AUS
NZ
UK
CA
USA
IND
Healthcare
PolyNovo (ASX:PNV) & Key Short Selling Market Trends
September 29, 2025 11:02 AM AEST| By SamThis article delves into the dynamics of short selling in the Australian stock market, focusing on PolyNovo Limited (ASX:PNV) and its recent market movements.
CSL in Focus: What the ASX 200 Signals About Growth
September 26, 2025 03:33 PM AEST| By SamCSL Limited (ASX:CSL) draws attention in the ASX 200, with valuation debates, steady earnings growth, and contrasting market sentiment shaping its outlook within Australia’s healthcare and stock market landscape.
Tariffs Pressure CSL as ASX 200 Edges Lower
September 26, 2025 03:04 PM AEST| By SamAustralian market edged lower as (ASX:CSL) fell on US tariff news, with technology weakness weighing while ASX mining stocks and ASX dividend stocks showed resilience.
Health Stocks Face Pressure Amid ASX 200 Pharma Tariff Clouds
September 26, 2025 02:44 PM AEST| By SamHealth and retail stocks face pressure as CSL (ASX:CSL) responds to US pharma tariffs while Premier Investments (ASX:PMV) battles Smiggle misconduct concerns, sparking caution across the broader ASX market.
CSL (ASX:CSL) US Tariff Impact: Key Insights for ASX 200 Investors
September 26, 2025 01:48 PM AEST| By SamCSL (ASX:CSL) faces challenges as US tariffs on pharmaceuticals impact profits, influencing ASX 200 biotech investors and short selling trends in Australia.
INOVIQ (ASX: IIQ) Advances Ovarian Cancer Detection, Gaining Spotlight in ASX 200 Landscape
September 26, 2025 12:16 PM AEST| By SamINOVIQ (ASX:IIQ) secures worldwide rights for novel ovarian cancer biomarker technology, advancing its EXO-OC test in early cancer detection and shaping the ASX 200 healthcare landscape.
Ansell Limited (ASX:ANN) Set for Growth in ASX 200 Market
September 26, 2025 11:34 AM AEST| By SamDetailed analysis of Ansell Limited (ASX:ANN) highlights earnings growth, market positioning, and its role in the ASX 200, offering insights into investor confidence and future performance.
Why Sigma Healthcare’s (ASX:SIG) Growth Outlook Keeps It in Focus
September 25, 2025 04:10 PM AEST| By SamSigma Healthcare (ASX:SIG) remains in focus as its elevated valuation highlights growth expectations, market resilience, and its critical role in Australia’s pharmaceutical distribution sector.
Cann Group’s ASX Quotation Sparks Market Attention
September 25, 2025 02:12 PM AEST| By SamCann Group (ASX:CAN) strengthens its capital base by quoting new securities on ASX, reinforcing its role in the medicinal cannabis sector and highlighting growth within Australia’s evolving healthcare market.
Ryman Healthcare Joins ASX 200 Landscape
September 25, 2025 02:06 PM AEST| By SamRyman Healthcare (ASX:RYM) secures ASX listing, strengthening investor access, expanding retirement living sector visibility, and enhancing growth prospects across New Zealand and Australia through its dual market presence.
Recce Pharmaceuticals (ASX:RCE) Starts Phase 3 Diabetes Trial
September 25, 2025 01:20 PM AEST| By SamRecce Pharmaceuticals (ASX:RCE) launches Phase 3 trial for its R327G gel targeting diabetic foot infections, addressing global diabetes challenges and advancing innovative solutions within the ASX 200 biotech sector.
Lumos Diagnostics Lights Up Investor Focus at ASX SMIDcaps
September 24, 2025 03:24 PM AEST| By SamLumos Diagnostics (ASX:LDX) strengthens visibility with its ASX SMIDcaps 2025 Conference appearance, showcasing rapid point-of-care diagnostic innovations and reinforcing its position within the evolving ASX stock market healthcare landscape.
Race Oncology Advances RC220 Trial with Korean Approval
September 24, 2025 12:34 PM AEST| By SamRace Oncology (ASX:RAC) gains Korean approval for its RC220 Phase 1 trial, expanding its global clinical footprint and advancing oncology research with a novel chemotherapy combination.
Pro Medicus (ASX:PME): Is the ASX 200 Giant Undervalued?
September 24, 2025 10:41 AM AEST| By SamExplore how Pro Medicus (ASX:PME) drives healthcare innovation, combines stability with growth, and strengthens its position within the ASX 200 through advanced digital imaging solutions.
Is the Share Price Attractive in 2025 of this ASX Stock?
September 23, 2025 05:31 PM AEST| By SamSonic Healthcare (ASX:SHL) remains a global healthcare leader. This article explores its valuation, financial health, and position within the ASX 200 in 2025.
Paragon Care (ASX:PGC) and the Fundamentals Driving Market Sentiment
September 23, 2025 05:12 PM AEST| By SamParagon Care (ASX:PGC) highlights long-term growth through reinvestment and stable fundamentals, showing resilience in healthcare despite market fluctuations and reflecting broader trends in the dynamic ASX stock market.
Neurizon’s ASX Securities Move Sparks Investor Curiosity
September 23, 2025 02:18 PM AEST| By SamNeurizon Therapeutics (ASX:NUZ) advances with new securities quotation on ASX, boosting visibility and capital access while strengthening biotech representation in the evolving Australian equities and broader ASX stock market landscape.
Bio-Gene (ASX:BGT) Launches Innovative Tick Solution
September 23, 2025 11:46 AM AEST| By SamBio-Gene (ASX:BGT) demonstrates Flavocide’s strong tick control, offering durable, safe solutions for public health and veterinary markets amid rising Lyme disease concerns.
Algorae Pharma (ASX:1AI) Expands Oncology Reach ANZ
September 23, 2025 11:32 AM AEST| By SamAlgorae Pharmaceuticals (ASX:1AI) partners with Sakar Healthcare to launch five oncology medicines in Australia and New Zealand, complementing ongoing validation trials.
Is CSL (ASX:CSL) Still Misunderstood in the ASX 200?
September 22, 2025 05:54 PM AEST| By SamCSL Limited (ASX:CSL) faces cautious sentiment despite resilient fundamentals. Strong return on equity and healthcare leadership highlight its enduring role in the ASX 200 and broader Australian market landscape.
Advertise your brand on Kalkine Media